Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients

Rafael Fonseca, Michael C. Trendle, Traci Leong, Robert A. Kyle, Martin M. Oken, Neil Elliot Kay, Brian Van Ness, Philip R. Grepp

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Bone involvement is a central feature of multiple myeloma (MM). We investigated whether serum markers of osteoblastic and osteoclastic activity correlate with the presence of bone disease and survival in 313 MM patients enrolled in a phase III trial (E9486). Five markers were measured, including osteocalcin (OC), carboxy-terminal propeptide of type I collagen (PICP), bone alkaline phosphatase (BAP), carboxy-terminal telopeptide of type I collagen (ICTP) and tartrate-resistant acid phosphatase (TRAP). We analysed the relationship between serum levels of these markers and the presence of bone manifestations, and survival. Serum levels of ICTP and BAP correlated significantly with bone pain, lesions and fractures. Serum level of ICTP was also higher in stage II-III compared with stage I disease. The serum level of ICTP was significantly associated with shortened survival in the univariate analysis. The median survival times were 4.1 and 3.5 years for low and high ICTP respectively (P = 0.02). There was a strong relationship between ICTP and beta-2-microglobulin (B2M). ICTP stands out as a significant marker of bone disease. Incorporation of these markers into clinical trials assessing the use of bisphosphonates in MM is needed to determine whether they might serve as indicators of effectiveness of these agents.

Original languageEnglish (US)
Pages (from-to)24-29
Number of pages6
JournalBritish Journal of Haematology
Volume109
Issue number1
DOIs
StatePublished - 2000

Fingerprint

Multiple Myeloma
Biomarkers
Bone and Bones
Survival
Bone Diseases
Collagen Type I
Alkaline Phosphatase
Serum
beta 2-Microglobulin
Osteocalcin
Diphosphonates
Clinical Trials
Pain

Keywords

  • Bone
  • Myeloma
  • Prognosis
  • Telopeptide

ASJC Scopus subject areas

  • Hematology

Cite this

Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. / Fonseca, Rafael; Trendle, Michael C.; Leong, Traci; Kyle, Robert A.; Oken, Martin M.; Kay, Neil Elliot; Van Ness, Brian; Grepp, Philip R.

In: British Journal of Haematology, Vol. 109, No. 1, 2000, p. 24-29.

Research output: Contribution to journalArticle

Fonseca, Rafael ; Trendle, Michael C. ; Leong, Traci ; Kyle, Robert A. ; Oken, Martin M. ; Kay, Neil Elliot ; Van Ness, Brian ; Grepp, Philip R. / Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. In: British Journal of Haematology. 2000 ; Vol. 109, No. 1. pp. 24-29.
@article{6b49af664cbd4eac9b2416e6bb977fe5,
title = "Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients",
abstract = "Bone involvement is a central feature of multiple myeloma (MM). We investigated whether serum markers of osteoblastic and osteoclastic activity correlate with the presence of bone disease and survival in 313 MM patients enrolled in a phase III trial (E9486). Five markers were measured, including osteocalcin (OC), carboxy-terminal propeptide of type I collagen (PICP), bone alkaline phosphatase (BAP), carboxy-terminal telopeptide of type I collagen (ICTP) and tartrate-resistant acid phosphatase (TRAP). We analysed the relationship between serum levels of these markers and the presence of bone manifestations, and survival. Serum levels of ICTP and BAP correlated significantly with bone pain, lesions and fractures. Serum level of ICTP was also higher in stage II-III compared with stage I disease. The serum level of ICTP was significantly associated with shortened survival in the univariate analysis. The median survival times were 4.1 and 3.5 years for low and high ICTP respectively (P = 0.02). There was a strong relationship between ICTP and beta-2-microglobulin (B2M). ICTP stands out as a significant marker of bone disease. Incorporation of these markers into clinical trials assessing the use of bisphosphonates in MM is needed to determine whether they might serve as indicators of effectiveness of these agents.",
keywords = "Bone, Myeloma, Prognosis, Telopeptide",
author = "Rafael Fonseca and Trendle, {Michael C.} and Traci Leong and Kyle, {Robert A.} and Oken, {Martin M.} and Kay, {Neil Elliot} and {Van Ness}, Brian and Grepp, {Philip R.}",
year = "2000",
doi = "10.1046/j.1365-2141.2000.01960.x",
language = "English (US)",
volume = "109",
pages = "24--29",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients

AU - Fonseca, Rafael

AU - Trendle, Michael C.

AU - Leong, Traci

AU - Kyle, Robert A.

AU - Oken, Martin M.

AU - Kay, Neil Elliot

AU - Van Ness, Brian

AU - Grepp, Philip R.

PY - 2000

Y1 - 2000

N2 - Bone involvement is a central feature of multiple myeloma (MM). We investigated whether serum markers of osteoblastic and osteoclastic activity correlate with the presence of bone disease and survival in 313 MM patients enrolled in a phase III trial (E9486). Five markers were measured, including osteocalcin (OC), carboxy-terminal propeptide of type I collagen (PICP), bone alkaline phosphatase (BAP), carboxy-terminal telopeptide of type I collagen (ICTP) and tartrate-resistant acid phosphatase (TRAP). We analysed the relationship between serum levels of these markers and the presence of bone manifestations, and survival. Serum levels of ICTP and BAP correlated significantly with bone pain, lesions and fractures. Serum level of ICTP was also higher in stage II-III compared with stage I disease. The serum level of ICTP was significantly associated with shortened survival in the univariate analysis. The median survival times were 4.1 and 3.5 years for low and high ICTP respectively (P = 0.02). There was a strong relationship between ICTP and beta-2-microglobulin (B2M). ICTP stands out as a significant marker of bone disease. Incorporation of these markers into clinical trials assessing the use of bisphosphonates in MM is needed to determine whether they might serve as indicators of effectiveness of these agents.

AB - Bone involvement is a central feature of multiple myeloma (MM). We investigated whether serum markers of osteoblastic and osteoclastic activity correlate with the presence of bone disease and survival in 313 MM patients enrolled in a phase III trial (E9486). Five markers were measured, including osteocalcin (OC), carboxy-terminal propeptide of type I collagen (PICP), bone alkaline phosphatase (BAP), carboxy-terminal telopeptide of type I collagen (ICTP) and tartrate-resistant acid phosphatase (TRAP). We analysed the relationship between serum levels of these markers and the presence of bone manifestations, and survival. Serum levels of ICTP and BAP correlated significantly with bone pain, lesions and fractures. Serum level of ICTP was also higher in stage II-III compared with stage I disease. The serum level of ICTP was significantly associated with shortened survival in the univariate analysis. The median survival times were 4.1 and 3.5 years for low and high ICTP respectively (P = 0.02). There was a strong relationship between ICTP and beta-2-microglobulin (B2M). ICTP stands out as a significant marker of bone disease. Incorporation of these markers into clinical trials assessing the use of bisphosphonates in MM is needed to determine whether they might serve as indicators of effectiveness of these agents.

KW - Bone

KW - Myeloma

KW - Prognosis

KW - Telopeptide

UR - http://www.scopus.com/inward/record.url?scp=0034073082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034073082&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2000.01960.x

DO - 10.1046/j.1365-2141.2000.01960.x

M3 - Article

C2 - 10848778

AN - SCOPUS:0034073082

VL - 109

SP - 24

EP - 29

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -